This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​Shanghai Pharmaceuticals' bid for Cardinal Malaysia subject to Mofcom’s approval

By MLex Staff ( November 15, 2017, 09:06 GMT | Insight) -- The takeover of Cardinal Malaysia by Shanghai Pharmaceuticals will require antitrust approval from China’s Ministry of Commerce. The Shanghai-based, state-controlled pharmaceutical company is expected to pay about $557 million to buy all of Cardinal Malaysia, a major pharma and medical device distributor in China, from US-listed Cardinal Health.The takeover of Cardinal Malaysia by Shanghai Pharmaceuticals will require antitrust approval from China’s Ministry of Commerce. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login